392 related articles for article (PubMed ID: 17233517)
1. The pharmacological management of spasticity.
Saulino M; Jacobs BW
J Neurosci Nurs; 2006 Dec; 38(6):456-9. PubMed ID: 17233517
[TBL] [Abstract][Full Text] [Related]
2. An approach to switching patients from baclofen to tizanidine.
Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
[TBL] [Abstract][Full Text] [Related]
3. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
Lapeyre E; Kuks JB; Meijler WJ
NeuroRehabilitation; 2010; 27(2):193-200. PubMed ID: 20871149
[TBL] [Abstract][Full Text] [Related]
4. Comparative profile of tizanidine in the management of spasticity.
Lataste X; Emre M; Davis C; Groves L
Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
[TBL] [Abstract][Full Text] [Related]
5. Managing spasticity with drugs.
Simon O; Yelnik AP
Eur J Phys Rehabil Med; 2010 Sep; 46(3):401-10. PubMed ID: 20927006
[TBL] [Abstract][Full Text] [Related]
6. Anti-spasticity medications.
Al-Shahrani AM
Saudi Med J; 2003 Jan; 24(1):19-22. PubMed ID: 12590267
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic interventions for reducing spasticity in cerebral palsy.
Patel DR; Soyode O
Indian J Pediatr; 2005 Oct; 72(10):869-72. PubMed ID: 16272661
[TBL] [Abstract][Full Text] [Related]
8. [Comparative effectiveness of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].
Lipták J
Ideggyogy Sz; 2013 Nov; 66(11-12):429. PubMed ID: 24555245
[No Abstract] [Full Text] [Related]
9. [Pharmacology of spasticity. Does therapy remain in deep sleep?].
Noth J
Nervenarzt; 2000 Dec; 71(12):927-8. PubMed ID: 11139987
[No Abstract] [Full Text] [Related]
10. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
Taricco M; Pagliacci MC; Telaro E; Adone R
Eura Medicophys; 2006 Mar; 42(1):5-15. PubMed ID: 16565680
[TBL] [Abstract][Full Text] [Related]
11. Drugs used to treat spasticity.
Kita M; Goodkin DE
Drugs; 2000 Mar; 59(3):487-95. PubMed ID: 10776831
[TBL] [Abstract][Full Text] [Related]
12. The management of cerebral palsy: subjectivity and a conundrum.
Bodensteiner JB
J Child Neurol; 1996 Mar; 11(2):75-76. PubMed ID: 8881980
[No Abstract] [Full Text] [Related]
13. [Dantrolene. Pharmacological and therapeutic aspects].
Gerbershagen MU; Fiege M; Krause T; Agarwal K; Wappler F
Anaesthesist; 2003 Mar; 52(3):238-45. PubMed ID: 12666006
[TBL] [Abstract][Full Text] [Related]
14. [New therapies for spastic movement disorders].
Benecke R; Patejdl R
MMW Fortschr Med; 2009 Oct; 151 Suppl 3():118-22. PubMed ID: 20623938
[No Abstract] [Full Text] [Related]
15. Dantrolene sodium for treatment of spasticity.
Med Lett Drugs Ther; 1974 Jul; 16(15):61-2. PubMed ID: 4843632
[No Abstract] [Full Text] [Related]
16. [Treatment of spasticity].
Autti-Rämö I
Duodecim; 1999; 115(8):877-85. PubMed ID: 11859520
[No Abstract] [Full Text] [Related]
17. Tizanidine for spasticity.
Med Lett Drugs Ther; 1997 Jul; 39(1004):62-3. PubMed ID: 9217694
[No Abstract] [Full Text] [Related]
18. [The pharmacology of spasticity].
Morel N
J Belge Med Phys Rehabil; 1980; 3(2):105-12. PubMed ID: 9139023
[No Abstract] [Full Text] [Related]
19. Dantrolene: new indication. Cerebral palsy in children: uncertain clinical benefit.
Prescrire Int; 2008 Dec; 17(98):237. PubMed ID: 19422149
[TBL] [Abstract][Full Text] [Related]
20. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Groves L; Shellenberger MK; Davis CS
Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
